Last updated on February 2018

A Multiple Dose Dose Escalation Trial of AEB1102 in Patients With AML or MDS

Brief description of study

This is the first study of the safety of increasing dose levels of AEB1102 in patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study will also evaluate the amounts of AEB1102 in blood, the effects of AEB1102 on blood amino acid levels and the antitumor effects of AEB1102.

Clinical Study Identifier: NCT02732184

Contact Investigators or Research Sites near you

Start Over

Dale Bixby, MD

Comprehensive Cancer Center at University of Michigan
Ann Arbor, MI United States
  Connect »

Geoffrey Uy, MD

Washington University Medical School
Saint Louis, MO United States
  Connect »

Benjamin Tomlinson, MD

University Hospitals Case Medical Center
Cleveland, OH United States
  Connect »

Hetty Carraway, MD

The Cleveland Clinic
Cleveland, OH United States
  Connect »

Michael Savona, MD

Vanderbilt-Ingram Cancer Center
Nashville, TN United States
  Connect »

Yair Levy, MD

Baylor Scott & White
Dallas, TX United States
  Connect »

Robert Collins, MD

University of Texas Southwestern Medical Center
Dallas, TX United States
  Connect »

Joseph Brandwein, MD

University of Alberta
Edmonton, AB Canada
  Connect »

Aaron Schimmer, MD

Princess Margaret Cancer Centre
Toronto, ON Canada
  Connect »

Sarit Assouline, MD

Jewish General Hospital
Montreal, QC Canada
  Connect »